The Emerging Landscape of GLP-1 RA Therapies
The founder and CEO of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.
Gen Li, PhD, CEO and cofounder of Phesi, spoke with The American Journal of Managed Care® about the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical trials to treat overlapping conditions.
- Over 100 diseases are currently being studied using GLP-1 RA therapies, according to a recent analysis from Phesi.
- The rapid growth of GLP-1 RA therapies creates an incentive for efficient and easily accessible clinical trial data.
Phesi provides artificial intelligence–driven insights to sponsors and providers to optimize clinical trial efficacy.
Author's summary: GLP-1 RA therapies are increasingly used to treat multiple diseases.
More News
- Here’s Why Millennials Are Drawn to Mamdani—and What We Can Do To Change That
- Technology Ventures Honors 2024 U.S. Patent Recipients
- ‘Jesus Christ is the way,’ President Oaks says in first interview as Church president
- Traditional ecological knowledge is under threat in the Vietnamese Mekong Delta
- Pinto, Cozens help Senators rally for 4-3 comeback win in shootout vs Kraken
- Northwest cloud band set to spread rain, thunderstorms over southeast Aus
- Flyers’ offense sputters in 5-2 loss to Jets – Philly Sports
- Sandy Creek retires Jabari Smith’s jersey | The Citizen
- Claims of political links to Paul Mashatile are just “gossip”, winning Lottery bidder says